Hemostatic Drug Info
Search the site
A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group.
Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII.
Inhibitor antibodies to factor VIII and factor IX: management.
New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate.
Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection.
Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VII and IX inhibitors.
Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use program in patients with severe hemophilia or with acquired inhibitors.
The treatment of bleeding in hemophilic patients with inhibitors with recombinant factor VIIa.
Treatment of bleeding episodes in patients with hemophilia and an inhibitor: comparison of two treatment protocols with recombinant activated factor VII.
Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with hemophilia and inhibitors.
Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease.
NovoSeven in immune tolerance therapy.
© Copyright 2002-2018 ~
All rights reserved.